To print: Select File and then Print from your browser's menu

Title: Citalopram Augmented With Carbamazepine In Depression Pilot Study

URL: http://www.elsevier.nl/cdweb/views/article.htt?
?jnl=0924977X&iss=3&vol=12&pii=S0924977X0200018

European Neuropsychopharmacology, 2002; 12: 255-260. "Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study"
05/15/2002 08:03:00 AM
By Elda Hauschildt

A pilot study suggests carbamazepine augmentation of citalopram therapy could be clinically useful in depressive patients who do not respond to citalopram alone. Adding carbamazepine can also lead to decreased plasma concentrations of the active enantiomer, escitalopram, according to European researchers who conducted an open study with four outpatients and two inpatients diagnosed with a major depressive episode. Participants were non-responders to four weeks pre-treatment therapy with citalopram. Some of the participants had comorbidities. Two patients had phobic anxiety disorder with panic attacks. Others comorbidities noted were generalised anxiety disorder, alcohol abuse, dependent personality disorder and hypertension. The investigators added carbamazepine during a second four-week drug therapy period. They report a slight but significant decrease in patient depression scores within one week of adding carbamazepine. Treatment was generally well tolerated. Adverse events included nausea in one patient, diarrhoea in one patient and rash in two. The researchers found a significant decrease in plasma concentrations of the citalopram eutomer S-citalopram (27 percent) and in R-citalopram (31 percent). They also observed a significant decrease in the ratio S/R-citalopram propionic acid derivative.

http://www.elsevier.nl/cdweb/views/article.htt?
?jnl=0924977X&iss=3&vol=12&pii=S0924977X0200018

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.